This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
AUA 2024
APCCC 2024
EAU 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ESMO 2017
ESMO 2017
Prostate Cancer
Bladder Cancer
Kidney Cancer
ESMO 2017 Prostate Cancer
Viewing 21-40 of 41 articles
ESMO 2017: ARASENS: A Phase 3 Trial of Darolutamide in Males with Metastatic Hormone-Sensitive Prostate Cancer
ESMO 2017: Stereotactic Ablative Radiotherapy (SABR) for Oligoprogressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) During Abiraterone Therapy: A Phase I Study
ESMO 2017: Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC)
ESMO 2017: Phase I study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer
ESMO 2017: Phase I, Open-label, Dose-Finding Study of GSK2636771, a phosphoinositide 3-kinase β inhibitor, in Combination with Enzalutamide in Male Subjects with Metastatic Castration-Resistant Prostate Cancer
ESMO 2017: Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence enhancement and tumor inhibition in advanced prostate cancer
ESMO 2017: Safety and Immunogenicity of a DNA-vaccine Immunotherapy in Men with Biochemically (PSA) Relapsed Prostate Cancer
ESMO 2017: Abiraterone acetate + Prednisolone for metastatic Castration-Resistant Prostate Cancer (mCRPC) with early progression or non-response to Androgen Deprivation Therapy
ESMO 2017: Randomized Controlled Trial Comparing Radiotherapy +/- Endocrine Therapy Versus Endocrine Therapy Alone for PSA Failure after Radical Prostatectomy: Japan Clinical Oncology Group Study JCOG0401
ESMO 2017: Prognostic Associations of PSA Decline with Survival, Radiographic Response and Progression in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide
ESMO 2017: DNA repair gene panel mutations in young onset and aggressive v non-aggressive prostate cancer cases in the UK
ESMO 2017: Panel Discussion – Targeted Alpha Therapy
ESMO 2017: The Future of Targeted Alpha Therapy
ESMO 2017: Case Studies in mCRPC – Navigating the Increasingly Busy Waters
ESMO 2017: The Evolving Landscape of Treating Advanced Prostate Cancer
ESMO 2017: PROREPAIR-B: A prospective cohort study of DNA repair defects in metastatic castration resistant prostate cancer
ESMO 2017: Adding abiraterone acetate plus prednisolone or docetaxel for patients with high-risk prostate cancer starting long-term androgen deprivation therapy: directly randomized data from STAMPEDE
ESMO 2017: Lutetium-177 PSMA (LuPSMA) Theranostics Phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA
ESMO 2017: Docetaxel with androgen suppression for high-risk localized prostate cancer patients who relapsed PSA after radical prostatectomy and/or radiotherapy: A randomized phase III trial
ESMO 2017: Benefits of Abiraterone Acetate Plus Prednisone When Added to Androgen Deprivation Therapy in LATITUDE on Patient Reported Outcomes
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free